Halozyme Therapeutics (HALO) Return on Capital Employed (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Return on Capital Employed data on file, last reported at 22.9% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 22.9%, down 728.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 22.9% (down 728.0% YoY), and the FY2025 annual result was 22.15%, down 920.0% from the prior year.
• Return on Capital Employed rose to 22.9% in Q1 2026 per HALO's latest filing, from 21.36% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 56.71% in Q3 2025 and troughed at 14.56% in Q3 2022.
• A 5-year average of 24.33% and a median of 22.69% in 2024 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2022 and 2025: Return on Capital Employed slumped 1536 bps in 2022, then soared 3206 bps in 2025.
• A 5-year view of Return on Capital Employed shows it stood at 15.53% in 2022, then gained by 28 bps to 19.85% in 2023, then jumped by 42 bps to 28.26% in 2024, then dropped by 24 bps to 21.36% in 2025, then grew by 7 bps to 22.9% in 2026.
• Business Quant data shows HALO's Return on Capital Employed at 22.9% in Q1 2026, 21.36% in Q4 2025, and 56.71% in Q3 2025.